Immudicon is a preclinical stage biotechnology company creating complement-based biologics that target and localize immune cells to the tumor.


The platform modulates chemical barriers within the tumor microenvironment that create an immunosuppressive shield around the tumor such as Interleukin-10.  


Currently, Immudicon has raised $1.5M and has partnered under paid agreements with several industry collaborators including Novartis. 


Immudicon is developing biologics that activate antigen-presenting immune cells against cancer

Direct Tumor Targeting
Cancer Vaccine (MacroVax)

© Copyright 2017 || Immudicon LLC

  • Angellist-icon
  • LinkedIn Social Icon
  • Facebook App Icon